BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17050870)

  • 21. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
    Ohe Y; Ichinose Y; Nakagawa K; Tamura T; Kubota K; Yamamoto N; Adachi S; Nambu Y; Fujimoto T; Nishiwaki Y; Saijo N; Fukuoka M
    Clin Cancer Res; 2008 Jul; 14(13):4206-12. PubMed ID: 18594001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
    Reid T; Valone F; Lipera W; Irwin D; Paroly W; Natale R; Sreedharan S; Keer H; Lum B; Scappaticci F; Bhatnagar A
    Lung Cancer; 2004 Sep; 45(3):381-6. PubMed ID: 15301879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.
    Jatoi A; Hillman S; Stella P; Green E; Adjei A; Nair S; Perez E; Amin B; Schild SE; Castillo R; Jett JR;
    J Clin Oncol; 2005 Dec; 23(36):9113-9. PubMed ID: 16361618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
    Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
    Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread.
    Friedberg JS; Mick R; Stevenson JP; Zhu T; Busch TM; Shin D; Smith D; Culligan M; Dimofte A; Glatstein E; Hahn SM
    J Clin Oncol; 2004 Jun; 22(11):2192-201. PubMed ID: 15169808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bexarotene ligand pharmaceuticals.
    Hurst RE
    Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
    Rinehart J; Adjei AA; Lorusso PM; Waterhouse D; Hecht JR; Natale RB; Hamid O; Varterasian M; Asbury P; Kaldjian EP; Gulyas S; Mitchell DY; Herrera R; Sebolt-Leopold JS; Meyer MB
    J Clin Oncol; 2004 Nov; 22(22):4456-62. PubMed ID: 15483017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients.
    Sun AS; Yeh HC; Wang LH; Huang YP; Maeda H; Pivazyan A; Hsu C; Lewis ER; Bruckner HW; Fasy TM
    Nutr Cancer; 2001; 39(1):85-95. PubMed ID: 11588907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
    Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
    Edelman MJ; Smith R; Hausner P; Doyle LA; Kalra K; Kendall J; Bedor M; Bisaccia S
    J Clin Oncol; 2005 Aug; 23(24):5774-8. PubMed ID: 16110034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
    Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
    Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
    Jänne PA; von Pawel J; Cohen RB; Crino L; Butts CA; Olson SS; Eiseman IA; Chiappori AA; Yeap BY; Lenehan PF; Dasse K; Sheeran M; Bonomi PD
    J Clin Oncol; 2007 Sep; 25(25):3936-44. PubMed ID: 17761977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
    Freidlin B; Breathnach OS; Johnson BE
    Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
    Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
    J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.